Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

Journal of hepatology - 1 Jun 2003

Schiff Eugene R, Dienstag Jules L, Karayalcin Selim, Grimm Ian S, Perrillo Robert P, Husa Petr, de Man R A, Goodman Zachary, Condreay Lynn D, Crowther Lynn M, Woessner Mary A, McPhillips Penny J, Brown Nathaniel A

Abstract excerpt

BACKGROUND/AIMS: Lamivudine is effective in treatment-naive patients with chronic hepatitis B, but its role in interferon nonresponders has not been described. We assessed lamivudine treatment, with or without added interferon, in patients with hepatitis B e antigen (HBeAg)-positive chronic hepat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 12763376
DOI: 10.1016/s0168-8278(03)00076-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12763376-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.PMID 12763376Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.Semantic proximity Read ↗

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.Semantic proximity Read ↗

Telbivudine versus lamivudine in patients with chronic hepatitis B.Semantic proximity Read ↗

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.Semantic proximity Read ↗

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.Semantic proximity Read ↗

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.Semantic proximity Read ↗

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy.Semantic proximity Read ↗

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.Semantic proximity Read ↗

Effective interferon therapy for chronic hepatitis C patients with low viral loads.Semantic proximity Read ↗

Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.